Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

NCT04435691 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

110

Enrollment

OTHER

Sponsor class

Stopped 75% \> Participants

Conditions

Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
BIOLOGICAL: Magrolimab
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]